Last updated: 22 March 2022 at 5:50pm EST

Kevin Broadfin Capital, Llc... Net Worth




The estimated Net Worth of Kevin Broadfin Capital, Llc... is at least $28.9 Million dollars as of 27 January 2022. Kevin Llc owns over 7,684 units of Biodelivery Sciences International stock worth over $28,878,907 and over the last 8 years Kevin sold BDSI stock worth over $0.

Kevin Llc BDSI stock SEC Form 4 insiders trading

Kevin has made over 7 trades of the Biodelivery Sciences International stock since 2019, according to the Form 4 filled with the SEC. Most recently Kevin exercised 7,684 units of BDSI stock worth $42,954 on 27 January 2022.

The largest trade Kevin's ever made was buying 300,000 units of Biodelivery Sciences International stock on 11 May 2021 worth over $960,000. On average, Kevin trades about 64,467 units every 75 days since 2016. As of 27 January 2022 Kevin still owns at least 5,166,173 units of Biodelivery Sciences International stock.

You can see the complete history of Kevin Llc stock trades at the bottom of the page.



Insiders trading at Biodelivery Sciences International

Over the last 21 years, insiders at Biodelivery Sciences International have traded over $111,671,776 worth of Biodelivery Sciences International stock and bought 1,813,177 units worth $5,352,510 . The most active insiders traders include International, L.P. Elliott, Associates, L.P. Elliott und Healthcare Master Fund Ltd .... On average, Biodelivery Sciences International executives and independent directors trade stock every 18 days with the average trade being worth of $420,648. The most recent stock trade was executed by Jeffrey Allen Bailey on 9 March 2022, trading 5,333 units of BDSI stock currently worth $29,811.



What does Biodelivery Sciences International do?

BioDelivery Sciences International, Inc. is a commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions. BDSI has built a portfolio of products that includes utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs. BDSI's marketed products address serious and debilitating conditions, including chronic pain and opioid-induced constipation.



Complete history of Kevin Llc stock trades at Avadel Pharmaceuticals plc und Biodelivery Sciences International

Insider
Trans.
Transaktion
Gesamtpreis
Kevin Broadfin Capital, Llc...
Optionausübung $28,123
27 Jan 2022
Kevin Broadfin Capital, Llc...
Kauf $320,000
12 Nov 2021
Kevin Broadfin Capital, Llc...
Kauf $894,566
5 Nov 2021
Kevin Broadfin Capital, Llc...
Optionausübung $44,100
6 Aug 2021
Kevin Broadfin Capital, Llc...
Kauf $960,000
11 May 2021
Kevin Broadfin Capital, Llc...
Optionausübung $44,100
7 Aug 2020
Kevin Broadfin Capital, Llc...
Optionausübung $79,741
13 Aug 2019


Biodelivery Sciences International executives and stock owners

Biodelivery Sciences International executives and other stock owners filed with the SEC include: